Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Breast cancer

ACE inhibitors and beta-blockers reduce risk of cardiotoxicity for some Herceptin patients

Researchers conclude that prophylactic use of lisinopril or carvedilol should be considered in patients who could benefit from anthracycline treatment prior to trastuzumab (Herceptin).

Lisinopril ACE inhibitor, molecular structure

Source: Shutterstock.com

Study found that for HER2-positive breast cancer patients who received an anthracycline alongside trastuzumab, cardiac prophylaxis in the form of an ACE inhibitor (pictured) or beta-blocker decreased the rate of cardiotoxicity by around 50%

Trastuzumab (Herceptin; Genentech) is an effective treatment for HER2-positive breast cancer but it is frequently associated with cardiac side effects.

In research presented at the American College of Cardiology’s Annual Scientific Session in Orlando, Florida (11 March 2018), researchers analysed data on 468 patients treated with trastuzumab who were randomly assigned to receive lisinopril (an ACE inhibitor), carvedilol (a beta-blocker) or placebo[1]. Patients were stratified by treatment with an anthracycline, such as doxorubicin.

The data showed no significant difference overall in rates of cardiotoxicity between the three groups. However, during the two-year follow up, among patients who received an anthracycline alongside trastuzumab, cardiac prophylaxis decreased the rate of cardiotoxicity by around 50%.

The team said the results indicated that prophylactic use of lisinopril or carvedilol should be considered in those patients who could benefit from anthracycline treatment prior to trastuzumab.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204705

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Lisinopril ACE inhibitor, molecular structure

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.